No profile data available.
Evoke Pharma, Inc. (EVOK) is a healthcare company in the digestive system treatment drugs industry, based in Solana Beach, United States, with about 3 full-time employees.
It reported revenue of $10.25 million for fiscal year 2024, up 97.8% from fiscal year 2023, and net income of -$5.35 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $4.28 million, up 61.4% from a year before. Its market capitalization was $18.95 million.
Figures from company filings and market data; latest fiscal year ended December 31, 2024.
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Evoke Pharma reported $10.25 million in revenue for fiscal year 2024, up 97.8% from $5.18 million in fiscal year 2023. In Q3 2025 revenue was $4.28 million.
$18.95 million.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Cumberland Pharmaceuticals Inc. (CPIX), Heron Therapeutics, Inc. (HRTX), Devonian Health Group Inc. (GSD.V), Jaguar Health, Inc. (JAGX).